Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.The Motley Fool • 04/14/24
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)Zacks Investment Research • 04/09/24
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung CancerBusiness Wire • 04/04/24
Merck Foundation announced ‘‘Diabetes and Hypertension'' Media Recognition Awards 2024 for Asian CountriesBusiness Wire • 04/03/24
Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American CountriesBusiness Wire • 04/03/24
Merck: We Were Wrong, But The Exuberance Is Overly Done Here (Rating Upgrade)Seeking Alpha • 04/03/24
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian CancerBusiness Wire • 04/03/24
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical EnrollmentBusiness Wire • 04/03/24
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in AdultsBusiness Wire • 03/28/24
Merck shares move higher as lung disorder drug secures ‘squeaky clean' label from FDAProactive Investors • 03/27/24